BioMarin Just Dropped 19%. The Fundamentals Say the Market's Wrong. The Chart Says It Could Be Even Wronger.

# BioMarin Just Dropped 19%. The Fundamentals Say the Market's Wrong. The Chart Says It Could Be Even Wronger.

Let's get the headline out of the way: BioMarin closed at $57.18 on October 2, down 2.16% for the day, and it has now fallen roughly 19% from its August 2026 high of ~$70.24. The stock is grinding toward its 52-week low, sitting at a market cap of about $11.1B. Nobody who bought into the summer rally is smiling.

But here's the part that always gets me with a name like this. The market isn't selling BioMarin because the business broke. It's selling it because it can't decide what to do with it.

The Good News Is Real

Let's not pretend otherwise. In Q2 2026, BioMarin posted revenue of $989.7 million, up roughly 20% year-over-year, and it beat consensus of around $932M. It raised full-year 2026 revenue guidance to $3.88B–$3.93B and non-GAAP EPS guidance to $4.9–$5.1. Gross margins held at a fat 79.5%. Free cash flow of $133.9M in the quarter, with about $734M of cumulative FCF across the trailing four quarters. Balance sheet carries $874M in cash against $4.2B in debt — not pretty, not catastrophic.

There's more. A binding Ascendis Pharma patent settlement over Yuviwel that hands BioMarin a 20% royalty on net sales — a zero-development-cost revenue stream, the kind a CFO dreams about. An $275M upfront (plus $215M in milestones) acquisition of Alesta Therapeutics for its ALE1 asset. Durable five-year Pompe disease data with no new safety signals. Pipeline optionality from nivudirsen (BMN 351) in Duchenne. An AI collaboration with Profluent for enzyme design.

This is not a company flailing. This is a company with a live, growing, heavily-optioned rare-disease franchise.

So Why the Hell Is It Cratering?

Because the tape is telling a different story, and the tape doesn't care about your pipeline.

Price is below its 20-day, 50-day, and 200-day moving averages. It dropped from ~$69 in late August to ~$67 in early September to ~$57 now. RSI(14) at 26.7 — deeply, classically oversold. There's no bullish divergence in sight. The downtrend is intact until someone proves otherwise by reclaiming $60.

And then there's the valuation, which is where my skepticism really wakes up. BioMarin trades at a trailing P/E of roughly 154x. On a forward basis, that compresses to about 8.58x. Read that twice. The market is pricing the stock as if earnings are about to explode — a PEG of 0.14, a forward multiple that implies the growth thesis lands exactly as drawn. That's not a conservative valuation. That's a faith-based valuation. When the stock was near $70, you were paying for perfection. At $57, you're still paying for it, just at a discount.

My Read

Here's the tension I'd act on. The fundamentals gave BioMarin every reason to hold up. The stock fell anyway, on momentum, on dilution overhang (that $719.24M ESOP shelf registration is real), on leverage, and on a market that apparently prefers its biotech momentum single-directional and up.

Technically, an oversold bounce off these levels is the more probable near-term play. The relevant support is the $52 Q2 low, with the $49.26 52-week low as the line in the sand. Resistance clusters at $60, then $65–$68. But this is not a "buy it blind" situation. BioMarin carries a binary event sitting right in the hallway: Q3 earnings on Monday, October 26, after the close. That's a double-digit mover on a good or bad print, and the tape is whippy enough that a beat could get sold into.

So where does that leave me? I'd be inclined to size small and wait for proof, not hope. A reclaim of $58 with a stop under $52, targeting the $65–$68 prior-consolidation zone, is a defensible tactical frame. But I would not chase the fall knife, and I would not marry the forward-multiple narrative — a stock trading at 154x trailing earnings is a stock that has already priced the good news, and the only way it gets worse from here is if the good news disappoints.

The contrarian tell is worth noting too: retail sentiment on this name is absurdly bullish, with one fellow confidently forecasting a $100 stock by 2027. I've never once lost money betting against a retail crowd that's having too much fun.

The setup favors a bounce, not a reversal. Until price reclaims $60 with conviction, the downtrend owns the tape. The business is fine. The price is a conversation the market is still losing to itself. I'll be watching $58, $52, and October 26.